Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Change in Accured Expenses (2022 - 2025)

Historic Change in Accured Expenses for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to $443000.0.

  • Century Therapeutics' Change in Accured Expenses fell 8033.73% to $443000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.5 million, marking a year-over-year increase of 3259.28%. This contributed to the annual value of $1.6 million for FY2024, which is 31945.21% up from last year.
  • Century Therapeutics' Change in Accured Expenses amounted to $443000.0 in Q3 2025, which was down 8033.73% from $707000.0 recorded in Q2 2025.
  • In the past 5 years, Century Therapeutics' Change in Accured Expenses ranged from a high of $2.9 million in Q3 2023 and a low of -$6.5 million during Q1 2025
  • In the last 4 years, Century Therapeutics' Change in Accured Expenses had a median value of $707000.0 in 2025 and averaged -$37666.7.
  • As far as peak fluctuations go, Century Therapeutics' Change in Accured Expenses crashed by 31086.57% in 2023, and later skyrocketed by 39705.88% in 2025.
  • Century Therapeutics' Change in Accured Expenses (Quarter) stood at $1.1 million in 2022, then tumbled by 310.87% to -$2.4 million in 2023, then surged by 221.74% to $2.9 million in 2024, then crashed by 84.76% to $443000.0 in 2025.
  • Its last three reported values are $443000.0 in Q3 2025, $707000.0 for Q2 2025, and -$6.5 million during Q1 2025.